Compare AbCellera Biologics Inc (ABCL) vs Dolby Laboratories, Inc. (DLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Dolby Laboratories, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.26 (market cap $2.35B), while Dolby Laboratories, Inc. trades at $50.33 (market cap $4.66B). The key difference: Dolby Laboratories, Inc. is the larger of the two by market cap, and Dolby Laboratories, Inc. pays a 2.86% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | DLB | |
|---|---|---|
Market Cap | $2.35B | $4.66B |
Sector | Health | Industrials |
52-Week High | $8.12 | $76.79 |
52-Week Low | $2.78 | $49.31 |
Enterprise Value | $1.99B | $4.12B |
Dividend Yield | — | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
DLB trades at $49.31, down 3.6% today, with technical indicators showing bearish momentum. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.37 versus $1.31 expected. Revenue remains stable at $1.35B for 2025, with robust gross margins of 87.44%. Recent developments include FDA progress for zervimesine in DLB psychosis and recognition as GM's 2025 Supplier of the Year.
Despite near-term technical weakness, DLB's patent-protected revenue streams and high profitability support long-term value. The consensus price target of $87.50 implies significant upside, but investors face risks from cyclical end-markets and potential dilution from drug development. The stock presents a contrarian opportunity with 47% analyst buy ratings amid current bearish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →
